Release date: 5 December 2006
Promoter – Financial Intermediary
Statens Serum Institut (“SSI”), Copenhagen.Location
Description
Construction of a multi-purpose production facility for vaccines and diagnostics at Statens Serum Institut.
Objectives
The project will increase SSI’s existing capacity for the development and production of vaccines and the carrying out of associated R&D.
Comments
Pharmaceutical.
Sector(s)
Proposed EIB finance (Approximate amount)
Up to DKK 252 million (EUR 33.8 million).
Total cost (Approximate amount)
Approximately DKK 505 million (EUR 67.7 million).
Environmental aspects
The project will not materially change current practice within the dedicated vaccine producing area. Other related activities will be carried out within existing facilities, making use of existing laboratories, pilot plants and clinical centres; an EIA is therefore not explicitly required under EU Directive 97/11. The promoter’s general compliance with environmental regulations whether the authorities have requested an EIA for the new facility will be verified during appraisal.
Procurement
The promoter is a State-owned enterprise and, as such, the following EC Directives on procurement apply: Directive 92/50 on service supply, Directive 93/37 on public works and Directive 93/96 on goods supply. Procedures for procuring specialised equipment and external services will be verified during appraisal.
Status
Signed - 21/12/2006
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).